| Patent Number |
Title Of Patent |
Date Issued |
| RE40278 |
Heterocyclic amines having central nervous system activity |
April 29, 2008 |
| Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula: ##STR00001## and pharmaceutically acceptable salts thereof wherein R.sub.1 and R.sub.2 are independently hydrogen, C.sub. |
| RE38452 |
Heterocyclic amines having central nervous system activity |
March 2, 2004 |
| Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula: ##STR1##and pharmaceutically acceptable salts thereof wherein R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alk |
| RE35840 |
Imidazo[1,5-a]quinolines for treatment of anxiety and sleep disorders |
July 7, 1998 |
| The present invention is to imidazo[1,5-a]quinolines (I) which are useful pharmaceutical agents for the treatment of anxiety, sleep disorders, panic states, convulsions and muscle disorders. |
| D428141 |
Spray bottle grip |
July 11, 2000 |
|
| D421120 |
Spray bottle grip |
February 22, 2000 |
|
| 7378511 |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
May 27, 2008 |
| The present invention provides the enzyme and enzymatic procedures for cleaving the .beta. secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associa |
| 7377894 |
Methods for creating a compound library and identifying lead chemical templates and ligands for |
May 27, 2008 |
| A method for developing a library of compounds, the compound library, a method for identifying ligands for target molecules, and a method for identifying lead chemical templates, which, for example, can be used in drug discovery and design are provided. Certain embodiments of these m |
| 7375187 |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
May 20, 2008 |
| The present invention provides the enzyme and enzymatic procedures for cleaving the .beta. secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associa |
| 7368536 |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
May 6, 2008 |
| The present invention provides the enzyme and enzymatic procedures for cleaving the .beta. secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associa |
| 7364866 |
Drosophila G protein coupled receptors, nucleic acids, and methods related to the same |
April 29, 2008 |
| The present invention provides Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells, and methods for its production. The invention also provides methods for the |
| 7358264 |
Statine derivatives for the treatment of Alzheimer's disease |
April 15, 2008 |
| The present invention relates to compounds of formula (I): ##STR00001## useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characteri |
| 7354724 |
Drosophila G protein coupled receptors, nucleic acids, and methods related to the same |
April 8, 2008 |
| The present invention provides a Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the |
| 7351738 |
Substituted ureas and carbamates |
April 1, 2008 |
| The invention provides compounds of formula I: ##STR00001## useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by |
| 7338965 |
3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines |
March 4, 2008 |
| The invention relates to substituted piperidine, piperazine, morpholine and thiomorpholine compounds useful in the treatment of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to pr |
| 7338953 |
Method of treating chronic fatigue syndrome |
March 4, 2008 |
| Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. |
| 7322965 |
Infection-resistant medical devices |
January 29, 2008 |
| A method for preventing medical device-associated microorganism infection includes the steps of providing a medical device and incorporating an effective amount of an oxazolidinone compound, such as linezolid, into the medical device. |
| 7312360 |
Substituted hydroxyethylamines |
December 25, 2007 |
| Disclosed are compounds of the formula ##STR00001## and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R3, R4, R5, R.sub.N, and R.sub.c are defined herein. These compounds interact with and inhibit the activity of the enzyme beta-secretase. Th |
| 7309811 |
Transgenic mice knockouts of BACE-1 |
December 18, 2007 |
| The invention provides transgenic animals that are heterozygous or homozygous for a nonfunctional allele of BACE-1. These animals show normal development indicating that BACE-1 is not necessary for development and hence is an appropriate therapeutic target. The transgenic animals are |
| 7291738 |
Therapeutic compounds |
November 6, 2007 |
| The present invention provides compounds, for example, of formula (I): ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic met |
| 7276503 |
Method of treating chronic fatigue syndrome |
October 2, 2007 |
| Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of t |
| 7262208 |
Hydroxypropyl amides for the treatment of Alzheimer's disease |
August 28, 2007 |
| The present invention relates to compounds of formula (I): ##STR00001## useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characteri |
| 7256189 |
3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors |
August 14, 2007 |
| The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders |
| 7247706 |
Double mutant alpha-7 nicotinic acetylcholine receptors |
July 24, 2007 |
| The invention relates ton novel methods for measuring ion channel transmission and methods and compositions useful in the indentification of ligand gated channel agonists and modulators. |
| 7247627 |
Salts and polymorphs of a pyrrole-substituted indolinone compound |
July 24, 2007 |
| The invention relates to non-hygroscopic salts of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[(2S)-2-h- ydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide, such as maleate salts, and to crystalline polymorphs of these salts. The invention further |
| 7244755 |
Hydroxypropylamines |
July 17, 2007 |
| Disclosed are compounds of formula I: ##STR00001## and the pharmaceutically acceptable salts thereof wherein the variables R.sub.N, R.sub.1, R.sub.2, R.sub.3, R.sub.P and R.sub.C are defined herein. These compounds are useful in treating Alzheimer's disease and other similar disease |
| 7244725 |
Acetyl 2-hydroxy-1, 3-diaminoalkanes |
July 17, 2007 |
| Disclosed are compounds of the formula: ##STR00001## where variables Z, X, R.sub.15, R.sub.2, R.sub.3, and R.sub.C are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other di |
| 7241762 |
Method of treating peripheral neuropathy |
July 10, 2007 |
| Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. |
| 7235655 |
Processes to prepare eplerenone |
June 26, 2007 |
| The present invention involves intermediates, including a 7.alpha.-substituted steroid (II), ##STR00001## and processes which are used to prepare eplerenone, a useful pharmaceutical agent. |
| 7232930 |
Compounds and methods for preparing methanesulfonamides |
June 19, 2007 |
| A process for preparing (S)-(-)-N-[4-[4-[ethyl(6-fluoro-6-methylheptyl)amino]-1-hydroxy]phenyl]me- thanesulfonamide hemifumarate salt, which comprises reacting N-[4-[(2S)-tetrahydro-5-hydroxy-2-furanyl]phenyl]methanesulfonamide(IIa) with fluoroamine (III) in the presence of triacetoxy |
| 7208591 |
G protein-coupled receptor-like receptors and modulators thereof |
April 24, 2007 |
| The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal acti |
| 7205120 |
Substrates and assays for .beta.-secretase activity |
April 17, 2007 |
| The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a .beta.-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed. |
| 7186539 |
Method for refolding enzymes |
March 6, 2007 |
| The invention provides methods for efficient recombinant expression, refolding, and purification of Beta-site APP cleaving enzyme (BACE) polypeptides. In various aspects, the method includes the steps of expressing a recombinant construct in bacteria, dissolving inclusion bodies with |
| 7176242 |
N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
February 13, 2007 |
| Disclosed are compounds of the formula ##STR00001## wherein the variables R.sub.N, R.sub.C, R.sub.1, R.sub.25, R.sub.2, and R.sub.3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of discorders such as |
| 7160544 |
Method of vaccinating vertebrates |
January 9, 2007 |
| The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock cop |
| 7141570 |
N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
November 28, 2006 |
| The present invention provides antibacterial agents having the formula I described herein. |
| 7119209 |
Process for preparing indolinone derivatives |
October 10, 2006 |
| The present invention refers to a process for preparing indolinone derivatives of the general formula (VI) as defined in the specification and intermediates of that process. |
| 7115747 |
Process for preparing oxazole intermediates |
October 3, 2006 |
| Disclosed are compounds of formula III and a process to prepare a compound of formula III ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.6 are defined herein, using a zinc chloride/optionally substituted oxazole adduct and an compound of formula I. Further disclosed are me |
| 7115565 |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
October 3, 2006 |
| Pharmaceutical compositions suitable for oral administration comprising paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and optionally but preferably a P-glycoprotein inhibitor. The composition may further comprise a diglyceride or mixture of diglyceride and mo |
| 7108864 |
Tablet formation |
September 19, 2006 |
| Disclosed is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegr |
| 7101888 |
Oral liquid tolterodine composition |
September 5, 2006 |
| A pharmaceutical composition in a form of an orally deliverable liquid comprises water having in solution therein a pharmaceutically acceptable water-soluble salt of a tolterodine related compound at a therapeutically effective concentration in the composition. The composition has a pH o |
| 7074927 |
Heterocyclic amines having central nervous system activity |
July 11, 2006 |
| Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula: ##STR00001## and pharmaceutically acceptable salts thereof wherein R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1 |
| 7067626 |
Human ion channel proteins |
June 27, 2006 |
| The present invention provides novel ion channel polypeptides and polynucleotides that identify and encode them. In addition, the invention provides expression vectors, host cells and methods for their production. The invention also provides methods for the identification of ion channel |
| 7067542 |
Diaminediols for the treatment of Alzheimer's disease |
June 27, 2006 |
| The present invention relates to compounds of formula (I): ##STR00001## useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characteri |
| 7067507 |
Macrocycles useful in the treatment of Alzheimer's disease |
June 27, 2006 |
| The present invention is macrocycles of the formula (X): ##STR00001## for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme for the treatment of Alzheimer's disease and other diseases characterized by deposition |
| 7053109 |
Aminediols for the treatment of Alzheimer's disease |
May 30, 2006 |
| The present invention relates to compounds of formula (I): ##STR00001## useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characteri |
| 7049443 |
Amide-containing compound having improved solubility and method of improving the solubility of a |
May 23, 2006 |
| The present invention is directed to novel amide-containing compounds which have an improved solubility and a method of improving the solubility of amide-containing compounds. The amide-containing compounds include oxazolidinone compounds and the bioavailability of these oxazolidinon |
| 7041473 |
Alzheimer's disease secretase, APP substrates therefor, and uses thereof |
May 9, 2006 |
| The present invention provides the enzyme and enzymatic procedures for cleaving the .beta. secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cell and cell isolates and assays. The invention further provides a modified APP protein and associat |
| 7030109 |
1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
April 18, 2006 |
| The present invention discloses radioligands of 9-arylsulfone of the formula (X) ##STR00001## or a pharmaceutically acceptable salt or enantiomer thereof, which are useful in diagnosing depression, obesity and other CNS disorders. |
| 7022694 |
Indoles and indolines having 5-HT activity |
April 4, 2006 |
| The present invention provides compounds of Formula (I): ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and --- have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides |
| 7012088 |
Indolone oxazolidinones and derivatives thereof |
March 14, 2006 |
| The present invention provides antibacterial agents of formula I described herein and intermediates for their preparation. |
